Retatrutide, a novel dual activator of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) target, is showing promising outcomes in preliminary clinical assessments . Ongoing https://bookmarksea.com/story21324439/retatrutide-emerging-studies-and-potential-therapeutic-uses